Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes (SMARTEST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03982381
Recruitment Status : Recruiting
First Posted : June 11, 2019
Last Update Posted : April 28, 2021
Uppsala University Hospital
Swedish Healthcare Regions
Swedish National Board of Health and Welfare
The Swedish National Diabetes Register
Information provided by (Responsible Party):
Uppsala University